August 6th 2020
Noopur S. Raje, MD, discusses recent findings with melflufen in relapsed/refractory multiple myeloma.
Luciano J. Costa, MD, PhD, discusses unmet needs in relapsed/refractory multiple myeloma.
Sagar Lonial, MD, FACP, discusses the FDA approval of belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
The FDA has approved belantamab mafodotin-blmf (Blenrep) as a treatment for patients with relapsed/refractory multiple myeloma who have received 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.
August 5th 2020
Noopur S. Raje, MD, discusses remaining questions in multiple myeloma.
August 4th 2020
Shaji K. Kumar, MD, discusses treatment discontinuation in the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.
August 3rd 2020
Saad Z. Usmani, MD, FACP, discusses the key takeaways from the randomized phase 2 SWOG 1211 trial in patients with newly diagnosed, high-risk multiple myeloma.
Subcutaneous daratumumab in combination with pomalidomide and dexamethasone showed an improvement in progression-free survival versus pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.
July 29th 2020
A biologics license application has been submitted to the FDA for idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.
Noopur S. Raje, MD, discusses the quadruplet therapies that are currently available for patients with multiple myeloma.
